论文部分内容阅读
作为血小板二磷酸腺苷(ADP)受体的拮抗剂,氯吡格雷的问世在动脉粥样血栓事件的预防以及经皮冠状动脉介入治疗(percutaneous transluminal coronary intervention,PCI)围手术期抗栓治疗领域可谓为一场革命。其可通过竞争性与ADP P2Y12受
As an antagonist of platelet adenosine diphosphate (ADP) receptor, the advent of clopidogrel in the prevention of atherothrombotic events and perioperative antithrombotic therapy in percutaneous transluminal coronary intervention (PCI) Can be described as a revolution. It is competitive with ADP P2Y12